RANI News and Press, Rani Therapeutics Holdings Inc. From 11/09/23

Rani Therapeutics Holdings Inc. (RANI) is expected to report $-0.47 for Q3 2023

- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline result...

2023-11-03 17:23:29 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Rani to cut 25% of workforce as it reprioritizes drug programs Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for...

2023-11-01 18:21:14 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics Financial information for Rani Therapeutics ...

- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready - - Expansion of manufacturing footprint is expected ...

– Daily administration for 60 days was well-tolerated with no treatment-related adverse events – – Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies – SAN JOSE, Calif., Oct. 25, 2023 (GLOBE ...

- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – - RaniPill® HC shortlisted as a finalist by ...

2023-10-16 13:36:37 ET Gainers: Tempest Therapeutics ( TPST ) +98% . Momentus ( MNTS ) +51% . PCTEL ( PCTI ) +47% . Almacenes Exito ( EXTO ) +33% . Mereo Biopharma Group Plc ( MREO ) +30% . Rani Therapeutics Holdings ( RANI...

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an ab...

2023-09-19 06:36:29 ET Summary RANI is developing a payload agnostic robotic pill (RaniPill) with enormous potential for penetration of several multi-billion injectable drug delivery markets. Pre-clinical and early-phase human studies consistently show effective and safe oral deli...